SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending due to strong preliminary financial results and significantly raised growth outlook, driven by robust demand for its AI data center connectivity solutions from major hyperscalers. The community is actively discussing its valuation and the ongoing relevance of its copper-based technology amidst recent market volatility.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending as the FDA issued a Complete Response Letter for its RGX-121 gene therapy for Hunter syndrome, citing trial design concerns and an ongoing clinical hold extended due to a potential adverse event in a related gene therapy utilizing the same AAV vector platform. The community is expressing significant disappointment over the rejection and its impact on RGNX's valuation, while also questioning the FDA's scrutiny of gene therapies and celebrating gains from short positions.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as recent weak guidance for the coming quarter has driven a sell-off and ignited community debate over decelerating automotive and industrial demand. While bears foresee further drops, bulls are underscoring the company's strategic pivot to AI data centers with a significant Nvidia partnership and a large share repurchase program.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending following its earnings report, sparking community discussion over a notable stock decline despite positive EPS growth and reaffirmed guidance, with many attributing the dip to revenue shifts while maintaining strong long-term confidence in its extensive backlog of critical government, defense, and nuclear contracts.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending following its strong earnings beat, raised guidance, and a new share repurchase program, which are driving renewed bullish sentiment and analyst upgrades. Community discussion centers on its perceived undervaluation and potential for a short squeeze, as the company emphasizes strategic AI innovations within the evolving gig economy.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is rallying on community excitement around imminent EU approval for its cancer therapeutic, Anktiva, and intensified discussions of an 'Immunotherapy 2.0' partnership with Saudi Arabia for broad cancer indications. Investors are anticipating a significant short squeeze, validating the company's undervalued platform against recent industry acquisitions and its mission to deliver 'unstoppable' cancer treatments.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is a top trending stock, buoyed by recent analyst upgrades and its pivotal role in the rapidly expanding AI data center infrastructure. The community is highly focused on its essential high-speed connectivity solutions, strategic optical technology acquisitions, and potential for significant growth driven by hyperscaler spending.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

With its upcoming earnings report sparking significant options activity, Fiserv (FISV) is trending amidst a polarized community debate: optimists highlight recent insider and institutional buying alongside deep undervaluation, while skeptics worry about the stock's persistent weakness and broader fintech sector headwinds exacerbated by AI disruption concerns.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending sharply lower following the abrupt departures of its CFO and General Counsel amid an accounting review and delayed financial filings, sparking intense community discussion about whether the significant sell-off is an extreme overreaction or indicative of severe internal control issues.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AGMB is experiencing heightened attention as a new IPO amid extreme volatility, with community discussions largely focused on its low float potentially fueling a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have received a consensus rating of "Hold" from the five brokerages that are currently covering the firm, Marketbeat.com reports. One...

Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights GUTS

The DJS Law Group announces that it is investigating claims on behalf of investors of Fractyl Health, Inc. (Fractyl Health or the Company) (NASDAQ: GUTS) for violations of the securities laws...

Fractyl Health Showcases 6-Month REMAIN-1 Data as Revita Curbs Post-GLP-1 Weight Regain

Fractyl Health (NASDAQ:GUTS) presented prospective, randomized, double-blind, controlled six-month data from its REMAIN-1 midpoint cohort pilot study, highlighting results the company said support...

<ul class="summary-bullets"><li>The results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial.&nbsp;</li><li>Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles.</li><li>Patient-reported outcomes also indicated reduced cravings for sweet foods.</li></ul>Fractyl Health, Inc. (GUTS) announced on Thursday positive six-month findings from its ongoing REMAIN-1 Midpoint Cohort, a study evaluating Revita for weight maintenance after patients discontinue GLP-1 therapy.The six-month data, covering 40 participants, suggest that Revita helps limit weight regain following GLP-1 discontinuation, with treated patients regaining 4.5% of weight versus 7.5% in the sham group.<h2 class="st-heading-2">Midpoint Study Shows Promising Results</h2>An exploratory analysis of those who lost above-median weight during the GLP-1 run-in showed a 70% relative reduction in post-GLP-1 weight regain for Revita-treated participants compared with sham.&nbsp;These results reinforce the device’s potential durability and support continued study in the pivotal REMAIN-1 trial. Beyond weight maintenance, Revita-treated participants demonstrated improvements in lipid profiles, including higher HDL cholesterol and a lower triglyceride-to-HDL ratio.&nbsp;Patient-reported outcomes also indicated reduced cravings for sweet foods, suggesting that the device may influence appetite and metabolism through gut-mediated mechanisms.However,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">Fractyl Health's stock</a> plummeted 63% in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React</h2>Despite the fall in the stock’s price, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_29_085922_png_07f795b807.webp" alt="GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits" width="930" height="110"><figcaption>GUTS’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said the product that reduces sweet cravings could be extremely profitable, highlighting huge market potential.<stembedurl>https://stocktwits.com/BioRich/message/643264512</stembedurl>Another user said they trusted the management and would hold the stock.&nbsp;<stembedurl>https://stocktwits.com/CocoPeechu/message/643264755</stembedurl>Revita, the main product from Fractyl Health, is meant to reshape the lining of the small intestine through a single, minimally invasive procedure. The FDA has granted Revita Breakthrough Device designation to help people maintain weight after stopping GLP-1 treatments.The company also outlined upcoming catalysts, including one‑year cohort readouts and pivotal REMAIN‑1 data later this year, which could support a future U.S. marketing application.GUTS stock has declined by over 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-now-stock-is-falling/cmyifBjR4KZ">NOW Stock Falls 9% After Q4 Beat: Why Have Analysts Cut Price Targets?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study? 

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.

Equity

Six-month data from 40 participants suggest that Revita helps limit weight regain after GLP-1 discontinuation.


HC Wainwright Forecasts Fractyl Health FY2030 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Fractyl Health in a research report issued to clients and investors on...

Short Interest in Fractyl Health, Inc. (NASDAQ:GUTS) Expands By 24.0%

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 11,893,654 shares, a growth...

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat reports. One...

Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat reports...

Fractyl Health (NASDAQ:GUTS) CEO Acquires $19,998.72 in Stock

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan bought 10,416 shares of the stock in a transaction on Thursday, December 4th. The stock was acquired at an average cost of...

Insider Buying: Fractyl Health (NASDAQ:GUTS) CEO Buys 10,416 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CEO Harith Rajagopalan bought 10,416 shares of the firm's stock in a transaction that occurred on Thursday, December 4th. The shares were acquired...

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Fractyl Health Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.18	--	--	N/A
Q3 '25	-$0.32	-$0.71	-124.97%	MISSED
Q2 '25	-$0.36	-$0.56	-56.76%	MISSED
Q1 '25	-$0.48	-$0.47	1.40%	BEAT
Q4 '24	-$0.44	-$0.52	-19.54%	MISSED

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest GUTS News

GUTSFractyl Health Inc.